Nanobiotix completes escalation portion of 2020-0123 study
This completed dose escalation portion of the 2020-0123 study determined the recommended dose for Phase 2 (RP2D) after determining injection feasibility and observing a favorable safety profile.
The biotech company adds that the dose expansion portion of Phase 1, designed to evaluate additional safety signals and assess early signs of efficacy, is ongoing.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction